New Role as Senior Vice President of People and Culture
Wilmington, NC, 15 November 2021 – Catalyst Clinical Research, a clinical development and global resourcing organization headquartered in Wilmington, NC, recently announced the hiring of Marshall Skelton, an HR professional with nearly three decades of experience in the pharmaceutical and drug industry, as SVP, People & Culture.
Skelton will head people operations and talent acquisition strategy and oversee employee retention and learning and development. Working closely with Catalyst’s People Operations team, he will also take on the leadership of diversity and inclusion initiatives and professional development programs.
Skelton has focused on building strong, high-performing culture in fast-growth global companies throughout his career, including Eli Lilly, aaiPharma, Inc., and General Electric Co. Having been supporting the Catalyst team for the past 18 months as a consultant, Skelton joined the organization full-time on November 8.
“I look forward to joining a team that has done an exceptional job building a vibrant culture of collaboration and teamwork,” Marshall said. “While working with the team during this consultancy, I’ve been impressed with the people, the direction of Catalyst, and their commitment to their people-first corporate culture. I am looking forward to contributing to the company’s impressive growth and important mission, both aligning with my personal values.”
Nick Dyer, Catalyst CEO, stated, Marshall brings a broad range of experiences that will be instrumental in shaping our People and Culture initiatives as we continue developing a diverse, engaged, and high-performing team across the globe. We are excited to have Marshall on board as a key member of our Executive Leadership Team.”
A long-time resident of Wilmington, N.C., Skelton and his family have strong ties to the community. He demonstrates his commitment by serving on several volunteer boards and commissions.
About Catalyst
Catalyst is a clinical development organization providing highly customizable clinical research solutions to the global biopharmaceutical industry through two established solutions: Catalyst Flex and Catalyst Oncology. With over 500 staff and offices in the US and EU, the company provides multi-therapeutic global resourcing and functional services through Catalyst Flex and a full-service oncology CRO offering through Catalyst Oncology. The company’s flexible service model is built from more than a decade of listening to customers, devising customer-centric solutions, and helping them drive breakthrough clinical development studies leveraging Catalyst’s expert teams and innovative technologies.
Catalyst is a portfolio company of NovaQuest Capital Management, LLC, a leading healthcare and life sciences investment firm.
